Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 12/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21769039 | 1.00 | ADORA3 (0.39) | ADORA3ADORA2AADORA2BADORA1CFTR | |
| SCHEMBL21780006 | 0.82 | MAPT (0.39) | — | |
| SCHEMBL21769082 | 0.81 | CHRM4 (0.37) | ADORA3ADORA2AADORA2B | |
| SCHEMBL21769012 | 0.74 | ALDH1A1 (0.37) | — | |
| SCHEMBL21769079 | 0.74 | NPC1 (0.46) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL21768927 | 0.74 | ADORA2A (0.42) | ADORA3ADORA2AADORA2BADORA1 | |
| Hydrochloric Acid SCHEMBL21768908 | 0.73 | ALDH1A1 (0.36) | — | |
| SCHEMBL21768996 | 0.71 | ALDH1A1 (0.43) | — | |
| SCHEMBL21769044 | 0.67 | POLB (0.43) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL21769073 | 0.66 | KDM4E (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200079793-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | CORVUS PHARMACEUTICALS, INC. | 2020-03-12 | — | — | US | disclosed |
| EP-3616753-A1 | COMPOUNDS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | Corvus Pharmaceuticals, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200079793-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | ADORA2A, ADORA2B, ADORA3 | ADORA3 3/4885ADORA2A 1/4885ADORA2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.